<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30064200</PMID>        <DateRevised>            <Year>2018</Year>            <Month>08</Month>            <Day>01</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">2005-9256</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Jul</Month>                        <Day>31</Day>                    </PubDate>                </JournalIssue>                <Title>Cancer research and treatment : official journal of Korean Cancer Association</Title>                <ISOAbbreviation>Cancer Res Treat</ISOAbbreviation>            </Journal>            <ArticleTitle>Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.4143/crt.2018.270</ELocationID>            <Abstract>                <AbstractText Label="Purpose" NlmCategory="UNASSIGNED">Tumor-infiltrating lymphocyte (TIL), programmed death-ligand 1 (PD-L1) expression and neutrophil-to-lymphocyte ratio (NLR) is associated to immunogenicity and prognosis of breast cancer. We analyzed baseline NLR, changes of NLR, TIL, and PD-L1 during neoadjuvant chemotherapy (NAC) and their clinical implication in triple-negative breast cancer (TNBC).</AbstractText>                <AbstractText Label="Materials and Methods" NlmCategory="UNASSIGNED">Between January 2008 to December 2015, 358 TNBC patients were analyzed. Baseline NLR, 50 paired NLR (initial diagnosis, after completion of NAC) and 34 paired tissues (initial diagnosis, surgical specimen after completion of NAC) were collected. Changes of TIL, CD4, CD8, forkhead box P3 (FOXP3), and PD-L1 expression were assessed with immunohistochemical stain.</AbstractText>                <AbstractText Label="Results" NlmCategory="UNASSIGNED">Low NLR (≤3.16) was associated to superior survival (overall survival; 41.83 months vs. 36.5 months, p=0.002; disease-free survival [DFS] 37.85 months vs. 32.14 months, p=0.032). Modest NLR change after NAC (-30%&lt;NLR change&lt;100%) showed prolonged DFS (38.37 months vs. 22.37 months, p=0.015). During NAC, negative or negative conversion of tumor PD-L1 expression was associated to poor DFS (34.77 months vs. 16.03 months, p=0.037), and same or increased TIL showed trends for superior DFS, but without statistical significance. Positive tumor PD-L1 expression (H-score ≥5) in baseline or post-NAC tissue was associated to superior DFS (57.6 months vs. 12.5 months, p=0.001 and 53.3 months vs. 18.9 months, p=0.04). Positive stromal PD-L1 expression in baseline was also associated to superior DFS (50.2 months vs. 20.4 months, p=0.002).</AbstractText>                <AbstractText Label="Conclusion" NlmCategory="UNASSIGNED">In locally advanced TNBC, baseline NLR, changes of NLR during NAC was associated to survival. Baseline PD-L1 expression and changes of PD-L1 expression in tumor tissue during NAC also showed association to prognosis.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Jieun</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Division of Medical Oncology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kim</LastName>                    <ForeName>Dong-Min</ForeName>                    <Initials>DM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Lee</LastName>                    <ForeName>Ahwon</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Research Institute, The Catholic University of Korea, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Department of Hospital Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>07</Month>                <Day>31</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Korea (South)</Country>            <MedlineTA>Cancer Res Treat</MedlineTA>            <NlmUniqueID>101155137</NlmUniqueID>            <ISSNLinking>1598-2998</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Neutrophil-lymphocyteratio</Keyword>            <Keyword MajorTopicYN="N">PD-L1</Keyword>            <Keyword MajorTopicYN="N">Triple-negative breast neoplasms</Keyword>            <Keyword MajorTopicYN="N">Tumor-infiltrating lymphocytes</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>05</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>07</Month>                <Day>26</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>8</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>8</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>8</Month>                <Day>2</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30064200</ArticleId>            <ArticleId IdType="pii">crt.2018.270</ArticleId>            <ArticleId IdType="doi">10.4143/crt.2018.270</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>